← ANALYST RATINGS · TIPRANKS

GeneDx Holdings (WGS): analyst forecast and price target

$63.61 −9.41% close 16.10.26 · market cap $2.1B · Healthcare · Medical - Diagnostics & Research IWM 0.05%
Price targets and ratings of

Analyst consensus

Strong Buy

6 Buy0 Hold0 Sell

Ratings of 6 analysts in the last 3 months

12-month forecast

$88.50+39.1% upside

Based on 6 price targets given in the last 3 months, the average target is $88.50, the highest $103, the lowest $63.00. The average is +39.1% from the last price of $63.61.

$50.00$100$150Jan 26AprJulOctJan 27AprJulOctHigh$103Average$88.50Low$63.00
Highest target $103 Average target $88.50 Lowest target $63.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% Guggenheim $74.00 → $83.00+12.2% Buy +30.5% Reiterated 01.10.26on TipRanks 08:35 −2.0%next day +2.3% · 5 days −5.9%
William Bonello★★★★★★★★★★#152 · hits 66% · avg +35.0% Craig-Hallum $103 Buy +61.9% Reiterated 22.09.26on TipRanks 11:55 −7.2%next day −5.4% · 5 days −15.3%
Keith Hinton★★★★★★★★★★#7123 · hits 80% · avg +7.0% Freedom Capital Markets $93.00 → $102+9.7% Buy +60.4% Reiterated 11.08.26on TipRanks Sep 27 05:10 +5.3%next day +0.5% · 5 days −6.2%
Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% BTIG $90.00 Buy +41.5% Reiterated 04.08.26on TipRanks 07:56 +2.7%next day −1.2% · 5 days +15.4%
Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% Canaccord Genuity $75.00 → $90.00+20.0% Buy +41.5% Reiterated 04.08.26on TipRanks 07:50 +2.7%next day −1.2% · 5 days +15.4%
David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% Piper Sandler $63.00 Buy −1.0% Reiterated 04.08.26on TipRanks 07:45 +2.7%next day −1.2% · 5 days +15.4%
Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% TD Cowen $55.00 → $85.00+54.5% Buy +33.6% Reiterated 15.07.26on TipRanks 08:55 +5.5%next day −6.2% · 5 days −4.4%
Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% Guggenheim $70.00 → $74.00+5.7% Buy +16.3% Reiterated 29.06.26on TipRanks 07:12 −2.7%next day −1.5% · 5 days −6.3%
Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% Jefferies $100 Buy +57.2% Reiterated 27.05.26on TipRanks 11:05 −2.5%next day +3.5% · 5 days +9.5%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering GeneDx Holdings

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Daniel Brennan★★★★★★★★★★TD Cowen · #271
Hits 58%280 of 485 Average return +21.8%
1 year Daniel Brennan★★★★★★★★★★TD Cowen · #271
Hits 58%280 of 485 Average return +21.8%
2 years Daniel Brennan★★★★★★★★★★TD Cowen · #271
Hits 58%280 of 485 Average return +21.8%

Most profitable

3 months Daniel Brennan★★★★★★★★★★TD Cowen · #271
Hits 58%280 of 485 Average return +21.8%
1 year Daniel Brennan★★★★★★★★★★TD Cowen · #271
Hits 58%280 of 485 Average return +21.8%
2 years Mark Massaro★★★★★★★★★★BTIG · #2635
Hits 40%198 of 498 Average return +5.7%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $88.00 at a price of $72.30 (+21.7%); now: $88.50 at $63.61 (+39.1%).

$80.00$100Sep 15Oct 1Oct 15Top analysts$85.80Average target$88.50Price$63.61

PriceAverage targetTop analysts’ target

Recommendation trend

0102014Oct 2513Nov161Dec5121Jan 2613111Feb177Mar131Apr132May95Jun87Jul12Aug101Sep81Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy1398000
Buy25712108
Hold000011
Sell000000

Earnings and sales forecast

Next report: 03.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $0.07 (from $0.07 to $0.08). Last quarter: $0.01.

Sales

Next quarter’s sales estimate — $123M (from $122M to $124M). Last quarter: $114M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About GeneDx Holdings
  • CEO: Katherine A. Stueland
  • Employees: 1,300
  • North Tower, Stamford, CT, 06902, US
  • www.genedx.com

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Data from the stock’s TipRanks forecast page, read 12 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗